Cargando…

Mechanisms regulating resistance to inhibitors of topoisomerase II

Inhibitors of topoisomerase II (topo II) are clinically effective in the management of hematological malignancies and solid tumors. The efficacy of anti-tumor drugs targeting topo II is often limited by resistance and studies with in vitro cell culture models have provided several insights on potent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ganapathi, Ram N., Ganapathi, Mahrukh K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2013
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3729981/ https://www.ncbi.nlm.nih.gov/pubmed/23914174 http://dx.doi.org/10.3389/fphar.2013.00089

Ejemplares similares

Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint
por: Kozuki, Toshiyuki, et al.
Publicado: (2017)

Casein kinase I δ/ɛ phosphorylates topoisomerase IIα at serine-1106 and modulates DNA cleavage activity
por: Grozav, Adrian G., et al.
Publicado: (2009)

Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia
por: Michelson, Andrew P., et al.
Publicado: (2020)

Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase II α gene transfer is independent of topoisomerase II β
por: Zhou, Z, et al.
Publicado: (2001)

Targeting Aurora A Kinase (AAK) in Platinum-Resistant High Grade Serous Ovarian Cancer
por: Ganapathi, Ram N., et al.
Publicado: (2020)

PLK3 amplification and tumor immune microenvironment of metastatic tumors are linked to adjuvant treatment outcomes in uterine serous cancer
por: Jones, Wendell, et al.
Publicado: (2022)

RNA Immune Signatures from Pan-Cancer Analysis Are Prognostic for High-Grade Serous Ovarian Cancer and Other Female Cancers
por: Jones, Wendell D., et al.
Publicado: (2020)

Pharmacokinetics of Oral Formulations of Gepotidacin (GSK2140944), a Triazaacenaphthylene Bacterial Type II Topoisomerase Inhibitor, in Healthy Adult and Adolescent Participants
por: Barth, Aline, et al.
Publicado: (2022)

Effect of safranal on the response of cancer cells to topoisomerase I inhibitors: Does sequence matter?
por: Lozon, Lama, et al.
Publicado: (2022)

Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma
por: Norris, Eric J, et al.
Publicado: (2019)

Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer
por: Patel, Jai N., et al.
Publicado: (2018)

Hyperthermia, thermotolerance and topoisomerase II inhibitors.
por: Kampinga, H. H.
Publicado: (1995)

Calmodulin inhibitor trifluoperazine in combination with doxorubicin induces the selection of tumour cells with the multidrug resistant phenotype.
por: Kamath, N., et al.
Publicado: (1993)

Metnase Mediates Resistance to Topoisomerase II Inhibitors in Breast Cancer Cells
por: Wray, Justin, et al.
Publicado: (2009)

CD26/dipeptidyl peptidase IV enhances expression of topoisomerase II alpha and sensitivity to apoptosis induced by topoisomerase II inhibitors
por: Sato, K, et al.
Publicado: (2003)

The Roles of DNA Topoisomerase IIβ in Transcription
por: Madabhushi, Ram
Publicado: (2018)

Differing Von Hippel Lindau Genotype in Paired Primary and Metastatic Tumors in Patients with Clear Cell Renal Cell Carcinoma
por: Vaziri, Susan A. J., et al.
Publicado: (2012)

Modulation in vitro and in vivo of cytotoxicity but not cellular levels of doxorubicin by the calmodulin inhibitor trifluoperazine is dependent on the level of resistance.
por: Ganapathi, R., et al.
Publicado: (1988)

Differential regulation of NF-κB activation and function by topoisomerase II inhibitors
por: Campbell, Kirsteen J, et al.
Publicado: (2006)

Clonal lineage of high grade serous ovarian cancer in a patient with neurofibromatosis type 1
por: Norris, Eric J., et al.
Publicado: (2018)

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines.
por: Houlbrook, S., et al.
Publicado: (1995)

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines
Publicado: (1996)

Predicting responses to sunitinib using single nucleotide polymorphisms: Progress and recommendations for future trials
por: Ganapathi, Ram N, et al.
Publicado: (2011)

Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
por: Ando, M., et al.
Publicado: (1997)

7-Ethyl-10-Hydroxycamptothecin, a DNA Topoisomerase I Inhibitor, Performs BRD4 Inhibitory Activity and Inhibits Human Leukemic Cell Growth
por: Wang, Airong, et al.
Publicado: (2021)

Artemisinin Derivatives Target Topoisomerase 1 and Cause DNA Damage in Silico and in Vitro
por: Kadioglu, Onat, et al.
Publicado: (2017)

A Unique Topoisomerase II Inhibitor with Dose-Affected Anticancer Mechanisms and Less Cardiotoxicity
por: Li, Zhi-Ying, et al.
Publicado: (2021)

Developmental regulation of Drosophila DNA topoisomerase II
Publicado: (1991)

Corrigendum: 7-Ethyl-10-Hydroxycamptothecin, A DNA Topoisomerase I Inhibitor, Performs BRD4 Inhibitory Activity and Inhibits Human Leukemic Cell Growth
por: Wang, Airong, et al.
Publicado: (2021)

Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma
por: Jiang, Lei, et al.
Publicado: (2023)

Apigenin directly interacts with and inhibits topoisomerase 1 to upregulate CD26/DPP4 on colorectal carcinoma cells
por: Fux, Julia E., et al.
Publicado: (2022)

PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies
por: Wang, Nannan, et al.
Publicado: (2022)

Ciprofloxacin is a potential topoisomerase II inhibitor for the treatment of NSCLC
por: KLOSKOWSKI, TOMASZ, et al.
Publicado: (2012)

Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics
por: Matias-Barrios, Victor M., et al.
Publicado: (2021)

The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy
por: Matias-Barrios, Victor M., et al.
Publicado: (2023)

Topoisomerase II: a fitted mechanism for the chromatin landscape
por: Roca, Joaquim
Publicado: (2009)

Modeling Allosteric Mechanisms of Eukaryotic Type II Topoisomerases
por: Evoli, Stefania, et al.
Publicado: (2023)

Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors.
por: Davies, S. L., et al.
Publicado: (1997)

Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
por: Li, Zhen, et al.
Publicado: (2020)

Erratum: Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma
por: Frontiers Production Office,
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ibc19jj5d09bdb55llsk1tkra1